Vasopressin Antagonists in Acute Heart Failure Syndromes

  • Cesare Orlandi
  • Filippo Brandimarte
  • Mihai Gheorghiade
Chapter

Abstract

The contribution of neurohormonal abnormalities in the pathophysiology of chronic heart failure (CHF) is well established. Attenuation of the excessive and continuous activation of angiotensin II and β-adrenergic receptors in patients with CHF with angiotensin-converting enzyme (ACE) inhibitors and beta-blockers, respectively, has resulted in substantial reductions in morbidity and mortality. However, it is not clear whether intervention with other neuroendocrine modulators (e.g., tumor necrosis factor [TNF] or endothelin) could result in similar benefits.

Keywords

Heart Failure Chronic Heart Fail Serum Sodium Pulmonary Capillary Wedge Pressure Worsen Heart Failure 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.
This is a preview of subscription content, log in to check access.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    Francis GS, Benedict C, Johnstone DE, et al. Comparison of neuroendocrine activation in patients with left ventricular dysfunction with and without congestive heart failure. A substudy of the Studies of Left Ventricular Dysfunction (SOLVD). Circulation. 1990;82:1724–29.PubMedGoogle Scholar
  2. 2.
    Michell RH, Kirk CJ, Billah MM. Hormonal stimulation of phosphatidylinositol breakdown with particular reference to the hepatic effects of vasopressin. Biochem Soc Trans. 1979;7:861–5.PubMedGoogle Scholar
  3. 3.
    Goldsmith SR, Francis GS, Cowley AW Jr, Levine TB, Cohn JN. Increased plasma arginine vasopressin levels in patients with congestive heart failure. J Am Coll Cardiol. 1983;1:1385–90.PubMedGoogle Scholar
  4. 4.
    Nakamura Y, Haneda T, Osaki J, Miyata S, Kikuchi K. Hypertrophic growth of cultured neonatal rat heart cells mediated by vasopressin V(1A) receptor. Eur J Pharmacol. 2000;391:39–48.CrossRefPubMedGoogle Scholar
  5. 5.
    Rouleau JL, Packer M, Moye L, et al. Prognostic value of neurohumoral activation in patients with an acute myocardial infarction: effect of captopril. J Am Coll Cardiol. 1994;24:583–91.PubMedCrossRefGoogle Scholar
  6. 6.
    Udelson JE, Smith WB, Hendrix GH, et al. Acute hemodynamic effects of conivaptan, a dual V(1A) and V(2) vasopressin receptor antagonist, in patients with advanced heart failure. Circulation. 2001;104:2417–23.CrossRefPubMedGoogle Scholar
  7. 7.
    Udelson JE, Orlandi C, Ouyang J, et al. Acute hemodynamic effects of tolvaptan, a vasopressin V2 receptor blocker, in patients with symptomatic heart failure and reduced LVEF: an international, multi-center, randomized, placebo-controlled trial. HFSA Annual Meeting, Washington, DC. J Card Fail. 2007.Google Scholar
  8. 8.
    Gheorghiade M, Niazi I, Ouyang J, et al. Vasopressin V2-receptor blockade with tolvaptan in patients with chronic heart failure: results from a doubleblind, randomized trial. Circulation. 2003;107:2690–6.CrossRefPubMedGoogle Scholar
  9. 9.
    Dzau VJ, Colucci WS, Williams GH, Curfman G, Meggs L, Hollenberg NK. Sustained effectiveness of converting-enzyme inhibition in patients with severe congestive heart failure. N Engl J Med. 1980;302:1373–9.PubMedCrossRefGoogle Scholar
  10. 10.
    Nitter-Hauge S, Brodwall EK, Rootwelt K. Renal function studies in hyponatremic cardiac patients with edema (dilution syndrome). Am Heart J. 1974;87:33–40.CrossRefPubMedGoogle Scholar
  11. 11.
    Paller MS, Schrier RW. Pathogenesis of sodium and water retention in edematous disorders. Am J Kidney Dis. 1982;2:241–54.PubMedGoogle Scholar
  12. 12.
    Dzau VJ, Packer M, Lilly LS, Swartz SL, Hollenberg NK, Williams GH. Prostaglandins in severe congestive heart failure. Relation to activation of the renin-angiotensin system and hyponatremia. N Engl J Med. 1984;310:347–52.PubMedGoogle Scholar
  13. 13.
    Anderson RJ, Cadnapaphornchai P, Harbottle JA, McDonald KM, Schrier RW. Mechanism of effect of thoracic inferior vena cava constriction on renal water excretion. J Clin Invest. 1974;54:1473–9.CrossRefPubMedGoogle Scholar
  14. 14.
    Schrier RW. Pathogenesis of sodium and water retention in high-output and low-output cardiac failure, nephrotic syndrome, cirrhosis, and pregnancy. N Engl J Med. 1988;319:1065–72.PubMedCrossRefGoogle Scholar
  15. 15.
    Schrier RW, Humphreys MH, Ufferman RC. Role of cardiac output and the autonomic nervous system in the antinatriuretic response to acute constriction of the thoracic superior vena cava. Circ Res. 1971;29:490–8.PubMedGoogle Scholar
  16. 16.
    Ishikawa S, Saito T, Okada K, Tsutsui K, Kuzuya T. Effect of vasopressin antagonist on water excretion in inferior vena cava constriction. Kidney Int. 1986;30:49–55.CrossRefPubMedGoogle Scholar
  17. 17.
    Riegger GA, Liebau G, Kochsiek K. Antidiuretic hormone in congestive heart failure. Am J Med. 1982;72:49–52.CrossRefPubMedGoogle Scholar
  18. 18.
    Szatalowicz VL, Arnold PE, Chaimovitz C, Bichet D, Berl T, Schrier RW. Radioimmunoassay of plasma arginine vasopressin in hyponatremic patients with congestive heart failure. N Engl J Med. 1981;305:263–6.PubMedCrossRefGoogle Scholar
  19. 19.
    Ikram H, Chan W, Espiner EA, Nicholls MG. Haemodynamic and hormone responses to acute and chronic frusemide therapy in congestive heart failure. Clin Sci (Lond). 1980;59:443–9.Google Scholar
  20. 20.
    Gheorghiade M, Gattis WA, O’Connor CM, et al. Effects of tolvaptan, a vasopressin antagonist, in patients hospitalized with worsening heart failure: a randomized controlled trial. JAMA. 2004;291:1963–71.CrossRefPubMedGoogle Scholar
  21. 21.
    Konstam MA, Gheorghiade M, Burnett JC Jr, et al. Efficacy of Vasopressin Antagonism in Heart Failure Outcome Study With Tolvaptan (EVEREST) Investigators. Effects of oral Tolvaptan in patients hospitalized for worsening heart failure: the EVEREST Outcome Trial. JAMA. 2007;297:1319–31.CrossRefPubMedGoogle Scholar
  22. 22.
    Gheorghiade M, Konstam MA, Burnett JC Jr, et al. Efficacy of Vasopressin Antagonism in Heart Failure Outcome Study With Tolvaptan (EVEREST) Investigators. Short-term clinical effects of tolvaptan, an oral vasopressin antagonist, in patients hospitalized for heart failure: the EVEREST Clinical Status Trials. JAMA. 2007;28;297:1332–43.CrossRefGoogle Scholar

Copyright information

© Springer-Verlag London Limited 2008

Authors and Affiliations

  • Cesare Orlandi
    • 1
  • Filippo Brandimarte
    • 2
  • Mihai Gheorghiade
    • 3
  1. 1.Otsuka Maryland Research InstituteRockvilleUSA
  2. 2.Department of Cardiovascular, Respiratory and Morphological SciencesUniversity of Rome “La Sapienza”RomeItaly
  3. 3.Division of CardiologyNorthwestern University, Feinberg School of MedicineChicagoUSA

Personalised recommendations